Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. حسب Cristina Dolciotti (16317330)

Effects of pre-medication and warming device on systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressures in dogs following pre-medication, induction and inhalant anesthesi... حسب Jacob P. Rastas (20642173)

الموضوعات:

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

The mean and standard deviation of parameters. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

Middle cerebral artery mean flow velocity at three time points. حسب Marco Carbonara (11483575)

الموضوعات:

MiR-129-5p levels were decreased in mouse depression models. حسب Qiaozhen Qin (13159201)

"…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. The gray points represent miRNAs with no significant change (p < 0.05, false discovery rate (FDR) q < 0.05), while red and blue points indicate upregulated and downregulated miRNAs (p < 0.05, FDR q < 0.05), respectively. …"

Change in rectal temperature following pre-medication, induction and inhalant anesthesia. حسب Jacob P. Rastas (20642173)

الموضوعات:

Primary and secondary efficacy end points (intention-to-treat population). حسب Benjamin R. Lewis (22279166)

الموضوعات:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. حسب Katherine Schubert (5452712)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. حسب Søren Egstrand (10906087)

"…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …"

Point cloud fusion instance effect. حسب Hongliang Zou (20707270)

الموضوعات:

Summary of post-treatment disease course measures from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. حسب Filip Stanicic (17808254)

الموضوعات:

Disease course measures after the PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from off-label medications clinical trials. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات: